Keros Therapeutics Files 8-K
Ticker: KROS · Form: 8-K · Filed: Mar 14, 2024 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | Mar 14, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
Keros Therapeutics filed a standard 8-K on 3/14/24. No major news yet.
AI Summary
Keros Therapeutics, Inc. filed an 8-K on March 14, 2024, to report other events and financial statements. The filing does not contain specific details about new events or financial figures within the provided text, but it serves as a standard regulatory update.
Why It Matters
This filing is a routine regulatory update for Keros Therapeutics, Inc., informing the SEC about significant events or financial updates that may impact investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting purposes and does not contain new material information that would inherently increase risk.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- March 14, 2024 (date) — Date of Report
- 001-39264 (other) — SEC File Number
- 81-1173868 (other) — I.R.S. Employer Identification No.
- 1050 Waltham Street, Suite 302 (address) — Principal executive offices
- Lexington, Massachusetts (location) — Principal executive offices location
- 02421 (other) — ZIP Code
- 617-314-6297 (phone_number) — Registrant's telephone number
FAQ
What is the purpose of this 8-K filing by Keros Therapeutics, Inc.?
The 8-K filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, intended to report 'Other Events' and 'Financial Statements and Exhibits'.
On what date was this 8-K filing reported?
The date of the earliest event reported is March 14, 2024.
What is the principal executive office address for Keros Therapeutics, Inc.?
The principal executive offices are located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
What is the SEC file number for Keros Therapeutics, Inc.?
The SEC file number for Keros Therapeutics, Inc. is 001-39264.
Does this filing contain specific details about new events or financial results?
The provided text of the 8-K filing indicates it is for 'Other Events' and 'Financial Statements and Exhibits' but does not contain specific details about new events or financial figures within the excerpt.
Filing Stats: 459 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-03-14 08:01:27
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto
Filing Documents
- kros-20240314.htm (8-K) — 36KB
- exhibit99131424pr.htm (EX-99.1) — 9KB
- 0001664710-24-000034.txt ( ) — 172KB
- kros-20240314.xsd (EX-101.SCH) — 2KB
- kros-20240314_lab.xml (EX-101.LAB) — 22KB
- kros-20240314_pre.xml (EX-101.PRE) — 13KB
- kros-20240314_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On March 14, 2024, Keros Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track designation for KER-050 (elritercept) for the treatment of anemia in adult patients with very low-, low-, or intermediate-risk myelodysplastic syndromes. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated March 14 , 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: March 14, 2024